摘要
目的:探讨重组人血管内皮抑制因子(recombinant human vascular endothelial growth inhiloitor-192,rhVEGI-192)对人肺腺癌裸鼠移植瘤的放射增敏作用。方法:采用原核表达rhVEGI-192,获得目的蛋白。通过肿瘤倍增时间,计算药物的增敏系数。通过建立人肺腺癌裸鼠移植瘤模型,荷瘤裸鼠随机分为4组:对照组、10Gy、rhVEGI-192、rhVEGI-192+10Gy。采用6MV-X线进行照射,照射剂量为10Gy。获得移植瘤标本,利用免疫印迹法检测移植瘤中VEGF(vascular endothelial growth factor)的表达变化。结果:SDS电泳结果显示,目的蛋白位于22k D左右。10Gy照射时,重组人血管内皮抑制因子的EF(enhancement factor)值为1.5。和空白对照组相比,rhVEGI-192组和10Gy组移植瘤的生长受到抑制(P<0.001),rhVEGI-192+10Gy组移植瘤生长显著抑制(P<0.001),rhVEGI-192+10Gy组移植瘤较10Gy组有明显生长抑制。和空白组相比,rhVEGI-192组VEGF表达减少,而10Gy组VEGF表达变化不明显,rhVEGI-192+10Gy组VEGF表达明显减少。rhVEGI-192+10Gy和rhVEGI-192组相比,VEGF表达减少。结论:rhVEGI-192联合照射能够减少VEGF的表达。这可能是rhVEGI-192的增敏机制之一。
Objective: To evaluate the mechanism of radiosensitivity of rhVEGI-192 on human lung adenocarcinoma grafted in nude mice. Methods: Tumor-bearing model was established by injecting 973 cells to nude mice. Mice bearing tumor were randomly divided into four groups: control group,rhVEGI-192 group,radiation group,rhVEGI-192 +10 Gy group. In radiation group,mice were treated with 6 MV X-ray on the tumor. A dose of 10 Gy was applied. VEGF which expressed in tumor are detected by western blot. Results: EF of rhVEGI-192 + 10 Gy group were 1. 5. Compared with control group,tumor growth in rhVEGI-192 group and 10 Gy group was inhibited( P 0. 001),tumor growth in rhVEGI-192 group + 10 Gy group was inhibited significantly( P 0. 001). Compared with 10 Gy group,tumor growth in rhVEGI-192 + 10 Gy group was inhibited significantly( P 0. 001). Compared with control group,VEGF level were decreased in rhVEGI-192 group,rhVEGI-192 + 10 Gy group.VEGF level were the same with 10 Gy group. Compared with rhVEGI-192 group,VEGF level was decreased in rhVEGI-192+ 10 Gy group. Conclusion: rhVEGI-192 + radiation can decrease mouse tumor VEGF level,down-regulation VEGF is the radioenhancement mechanism of rhVEGI-192.
作者
程小峰
高春玲
谈文娟
王笑良
张蓓蓓
张娇
章志勇
Cheng Xiaofeng;Gao Chunling;Tan Wenjuan;Wang Xiaoliang;Zhang Beibei;Zhang Jiao;Zhang Zhiyong(Chenggong Hospital Affiliated to Xiamen University & the 174th Hospital of the Chinese People's Liberation Army, Xiamen 361001, Fujian , China;Medical College of Xiamen University, Xiamen 361001, Fujian, China)
出处
《肿瘤预防与治疗》
2018年第2期73-77,共5页
Journal of Cancer Control And Treatment
基金
中国人民解放军南京军区医学科技创新项目(编号:No.12MA061)